NMRA250117C20000
- 0.05
- 0.000.00%
Neumora Therapeutics Newsroom
Neumora Therapeutics Shares Are Trading Higher. B of A Securities Maintained a Buy Rating on the Stock.
B of A Securities Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA) and Idexx Laboratories (IDXX)
Trending Stocks as Wall Street Steps Into First Days of 2025 With Cautiousness
Sector Update: Health Care Stocks Higher Friday Afternoon
Neumora Therapeutics Up Over 16%, on Pace for Largest Percent Increase Since December 2023 -- Data Talk
Neumora Has 2 More Chances With Navacaprant After Readout Miss, Mizuho Says
Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday
J.P. Morgan Maintains Neumora Therapeutics(NMRA.US) With Hold Rating
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $23 to $30
Neumora Therapeutics Selloff Seen as Overdone -- Market Talk
Neumora Therapeutics' Navacaprant Did Not Meet Primary Endpoint in Depression
Hold Rating for Neumora Therapeutics Amid Disappointing Phase 3 Trial Results and High-Risk Pipeline Dependency
U.S. stocks fluctuate丨Neumora surged over 8% in after-hours trading after a failure in the final stage of its experimental depression medication research.
On January 3, Glonghui reported that Neumora Therapeutics (NMRA.US) plummeted 81.42% overnight, followed by an 8.12% increase in after-hours trading, closing at $2.13. Regarding the news, the company announced on Thursday that its experimental drug for treating severe depression showed no efficacy in the final stage of research, as patients receiving navacaprant treatment did not exhibit significant improvements in depression symptom measurements statistically. Neumora is conducting two additional final phase trials for this drug and is developing other medications for brain disorders. (Glonghui)
Antidepressant drug development failed! Neumora's stock price plummeted over 80% in a single day, marking the largest single-day drop since its listing.
The experimental depression medication navacapant did not show significant effects on depression in a clinical trial involving 383 patients, with no significant difference compared to the placebo effect.
Futu Morning News | The first show of the US stock market in the new year was turbulent, with Tesla falling over 6%, dragging down the Nasdaq; is the windfall for nuclear energy coming? AI Nuclear Power Concept stock Constellation rose over 8% against the
The revision of the final value of the USA manufacturing PMI for December releases Bullish Signals; Trump will hold a rally in Washington D.C. on the eve of the presidential inauguration; Tesla's Cybertruck is eligible this year for the maximum $7,500 USA tax credit.
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA
U.S. Small Caps Close Mixed As Rigetti Computing Lead, Neumora Therapeutics Lags